[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-bypass-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-bypass-surgery":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,85,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":19},"100640765","phase-2-anakinra-for-the-treatment-of-postprandial-hypoglycemia-in-a-patient-with-total-gastrectomy-and-end-stage-renal-disease-100640765",false,"NCT07580079","Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease","Anakinra for the Treatment of Recurrent Postprandial Hypoglycemia After Total Gastrectomy in a Patient With End-Stage Renal Disease","AnPHy-ReD","This is an N-of-1 Trial, tailored-designed to a single participant.\n\n* total gastrectomy\n* severe episodes of postprandial hypoglycaemia after total gastrectomy","MALE",{"count":19,"type":20},1,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Post-meal low blood sugar (postprandial hypoglycemia) is a common problem after certain stomach surgeries like gastric bypass or stomach removal. It usually happens 1 to 3 hours after eating and can cause symptoms such as tiredness, hunger, sweating, dizziness, trouble speaking, or even fainting. Right now, there is no approved medication for this condition-only a careful diet reduced in sugars and refined carbohydrates can sometimes help reduce symptoms.\n\nThe AnPHy-ReD study is a personalized research study, designed for just one patient. This patient is a 52-year-old man who has been struggling with severe post-meal low blood sugar ever since his stomach was removed due to tumor in 2017. He also has end-stage kidney disease and needs dialysis three times a week.\n\nThe study is being conducted at the Cantonal Hospital of Olten in Switzerland and lasts 10 weeks, including 24 study visits. Most of these visits will happen during the patient's regular dialysis sessions. For 6 weeks, the patient will take either the drug Anakinra or a placebo (a substance with no active ingredient), in a randomly chosen order. Neither the patient nor the doctors will know which one he is taking at any given time.\n\nDuring the study, the medical team will perform various tests, including physical check-ups and blood samples to look at sugar levels, various hormone levels and inflammation in the body. The patient will also wear a continuous glucose monitor (CGM) to track his blood sugar levels 24\u002F7. In addition, he will do several mixed meal tests-this means drinking a shake containing fats, proteins, and sugars during a study appointment to see in real time how his body processes food, with doctors measuring changes in blood sugar, hormone and inflammation markers over time. During the study duration any side effects or symptoms will be closely monitored.\n\nAt the end of the study, the team will compare the results between the times the patient took Anakinra and the times he took the placebo. This will help find out if Anakinra can reduce sharp drops in blood sugar after meals and improve his overall condition.",[26,27,28,29,30,31],"Postprandial Hypoglycemia","End-stage Renal Disease (ESRD)","Gastrectomy","Glucose Metabolism Disorders","Inflammation","Gastric Bypass Surgery",[26,33,34,35,36,30],"End-Stage Renal Disease","Anakinra","Gastric Bypass","IL-1 receptor antagonist","NOT_YET_RECRUITING","2026-05-05",{"date":40,"type":41},"2026-05-12","ACTUAL",{"date":43,"type":20},"2026-07",{"date":45,"type":20},"2026-12",{"name":47,"class":48},"Marc Donath","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100582875","study-of-the-link-between-mash--metabolic-dysfunction-associated-steatohepatitis-and-mams-mitochondria-associated-membranes--alteration-in-patients-undergoing-bariatric-surgery---mamba-100582875","NCT06868992","Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA","Study of the Link Between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) Alteration in Patients Undergoing Bariatric Surgery - MAMBA","MAMBA","* Inclusion Criteria \\* :\n\n  * Female or male adult patients\n  * Patient who has benefited from a pluridisciplinary evaluation (medical, surgical, psychiatric), with a favorable opinion for a sleeve gastrectomy or a gastric bypass.\n  * Patient with an indication Indication for intraoperative liver biopsy due to suspected MASH\n  * Patient who agrees to be included in the study and who signs the informed consent form,\n  * Patient affiliated to a healthcare insurance plan.\n* Exclusion Criteria \\* :\n\n  * Patient presenting Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).\n  * Patient presenting previous or current infection with Hepatitis C\n  * Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.\n  * Patient presenting Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.\n  * Patient presenting Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease.\n  * Patient presenting Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency.\n  * Patient presenting Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y\u002FH63D.\n  * Patient presenting Drug-induced liver disease as defined on the basis of typical exposure and history.\n  * Patient presenting Bile duct obstruction as shown by imaging studies.\n  * History of ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, methotrexate, amiodarone or tetracycline in the previous 6 months.\n  * Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices\n  * Consommation régulière et\u002Fou excessive d'alcool (plus de 30g\u002Fj pour les hommes et plus de 15 g\u002Fj pour les femmes) sur une période de plus de 2 ans au cours des 10 dernières années.\n  * History of known HIV infection\n  * History of type 1 diabetes\n  * Pregnant women or breastfeeding mothers\\*.\n  * Minor patient\n  * Patient deprived of liberty,\n  * Patients under psychiatric care\n  * Patients admitted to a health or social care establishment for purposes other than research\n  * Mentally unbalanced patients, under supervision or guardianship,\n  * Patients not affiliated to a social security scheme or benefiting from a similar scheme\n  * Patient who does not understand French\u002F is unable to give consent,\n  * Patient already included in a trial who may interfere with the study","ALL","18 Years","99 Years",{"count":61,"type":20},20,"OBSERVATIONAL","The main research hypothesis is that alterations in the communication between the endoplasmic reticulum (ER) and the mitochondria at contact sites called mitochondria-associated membranes (MAMs) occurs in different hepatic cell types of patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD) and is involved in the progression towards MASH and could also influence the process of improvement of MASH.\n\nThis study aims to investigate the link between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) in liver cells and peripheral blood mononuclear cells (PBMCs) in patients undergoing bariatric surgery. The primary objective is to analyze MAMs alterations in hepatocytes in MASH patients compared to non-MASH patients. Secondary objectives include evaluating the correlation between MAMs in PBMCs and liver cells and assessing MAMs changes post-bariatric surgery.",[65,66,67,31],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","Sleeve Gastrectomy",[69,70,71,72,73],"MASH","MASLD","Mitochondria-Associated Membranes (MAMs)","Bariatric Surgery","Hepatic Fibrosis","RECRUITING","2026-01-14",{"date":77,"type":41},"2026-01-15",{"date":79,"type":41},"2025-04-15",{"date":81,"type":20},"2028-03",{"name":83,"class":48},"Hospices Civils de Lyon",2,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":57,"minAge":58,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":96,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":19},"100611263","efficacy-of-oversewing-versus-surgical-ligation-clips-for-staple-line-reinforcement-of-the-gastric-pouch-to-reduce-post-operative-bleeding-in-laparoscopic-one-anastomosis-gastric-bypass-100611263","NCT07238309","Efficacy of Oversewing Versus Surgical Ligation Clips for Staple Line Reinforcement of the Gastric Pouch to Reduce Post Operative Bleeding in Laparoscopic One Anastomosis Gastric Bypass","A Comparative Study to Evaluate Efficacy of Oversewing Versus Surgical Ligation Clips for Staple Line Reinforcement of the Gastric Pouch to Reduce Post Operative Bleeding in Laparoscopic One Anastomosis Gastric Bypass","Inclusion Criteria:\n\n* ✔ Age ≥ 18years old\n\n  * Sex: both sex\n  * Fit for bariatric surgery\n  * body mass index (BMI) of 40 kg\u002Fm 2 or higher or BMI between 35 and 40 kg\u002Fm2 with significant comorbidities, such as T2DM, hypertension, OSAS or significant osteo- articular alterations, not responsive to medical therapies\n  * Patients should have tried and failed to lose weight using diet, exercise, and\u002For medication for at least 6 months\n  * Patients or first guardians accept to participate in the current study\n  * Patients or first guardians accept to provide informed written consent\n\nExclusion Criteria:\n\n* Patients less than 18 years old\n\n  * Patients or first guardians refused to participate in the current study\n  * Patients or first guardians refused to provide informed written consent\n  * All patients with bleeding disorders and patients needing re-exploration for bleeding other than staple line Pregnant or breastfeeding women",true,"80 Years",{"count":95,"type":20},30,[97],"NA","1. To test if there is a significant differences between Oversewing versus surgical ligation clips for staple line reinforcement of the gastric pouch regarding the reduction of post operative bleeding and the need for blood transfusions in laparoscopic one anastomosis gastric bypass.\n2. To assess whether oversewing or the use of surgical clips is more effective in reducing operative time and Cost analysis in (OAGB).\n3. To Provide evidence-based recommendations on staple line reinforcement techniques in OAGB, emphasizing patient safety and procedural efficiency",[31],[101],"Laparoscopic One Anastomosis Gastric Bypass surgery","2025-11-15",{"date":104,"type":41},"2025-11-20",{"date":106,"type":41},"2025-05-18",{"date":108,"type":20},"2026-06",{"name":110,"class":48},"Cairo University",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":92,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":19},"100552113","glucose-monitoring-in-treatment-of-postprandial-hypoglycemia-after-gastric-bypass-surgery-100552113","NCT06468865","Glucose Monitoring in Treatment of Postprandial Hypoglycemia After Gastric Bypass Surgery","Continuous Glucose Monitoring in Treatment of Postprandial Hypoglycemia After Gastric Bypass Surgery: The HypoSurge Randomized Clinical Trial","HypoSurge","Inclusion Criteria:\n\n* Gastric bypass surgery at least 1 year ago\n* Age ≥18 years\n* Symptomatic postprandial hypoglycaemia; capillary glucose level \\\u003C3.0 mmol\u002FL 1-4 hours after meals\n\nExclusion Criteria:\n\n* Not able to give informed consent\n* Reduced compliance due to severe mental and psychiatric conditions\n* Use of insulin or sulfonylureas\n* Use of systemic corticosteroids\n* Primary or secondary adrenal insufficiency\n* Insulinoma\n* Severe heart-, lung, liver- or kidney disease, cancer, malnutrition and other medical conditions causing fragility\n* Performed bariatric revisional surgery\n* Drug- or alcohol abuse\n* Pregnancy\n* Use of acarbose or octreotide in the treatment of postprandial hypoglycemia\n* Use of continuous glucose monitor",{"count":120,"type":20},100,[97],"The goal of this clinical trial is to learn if continuous glucose monitoring works to treat postprandial hypoglycaemia in patients who have undergone gastric bypass surgery. The main question it aims to answer is:\n\n• Is continuous glucose monitoring superior to usual care for prevention of postprandial hypoglycaemia in patients with verified postprandial hypoglycaemia after gastric bypass surgery?\n\nResearchers will compare continuous glucose monitoring to usual care to see if continuous glucose monitoring works to treat postprandial hypoglycaemia.\n\nParticipants will:\n\n* Use a continuous glucose monitor for 6 weeks or use no continuous glucose monitor for 5 weeks and wear a blinded continuous glucose monitor for 1 week.\n* Visit the clinic 2-3 times and have 2-3 phone consultations.\n* Register symptoms of hypoglycaemia, answer questionnaires, undergo a 24-hour dietary recall interview conducted by a registered dietitian, measure weight and body composition and take blood samples.",[124,31],"Hypoglycemia Non-Diabetic","2024-11-01",{"date":127,"type":41},"2024-11-05",{"date":129,"type":20},"2024-11-12",{"date":131,"type":20},"2026-12-31",{"name":133,"class":48},"Sykehuset i Vestfold HF"]